Given the relatively poor prognosis associated with end-stage heart failure, investigators and clinicians have long searched for therapies that alleviate or reverse the progressive loss of pump function that typifies a failing heart. The predominant strategy employed over the past two decades has been based on pharmacologic manipulation of cardiac contractility, aimed at agonizing or antagonizing beta-adrenergic receptor activity or the downstream accumulation of cAMP. Here we have identified a novel signaling pathway that utilizes PKCa as a feedback regulator to dampen cardiac contractility, presumably in response to periods of enhanced inotropic drive. Indeed, loss of PKCalpha through gene targeting revealed a hypercontractile phenotype, while PKCalpha overexpression in transgenic mice or acutely in isolated adult rat myocytes showed reduced contractility, supporting our first hypothesis that PKCalpha functions within a negative contractility feedback pathway in the heart. Augmentation in cardiac function observed in the absence of PKCalpha rescued a model of pressure overload-induced heart failure, supporting our second hypothesis that selective enhancement of cardiac contractility can benefit a failing heart. To examine these two hypotheses we will: 1) define the biochemical mechanism whereby PKCalpha regulates cardiac contractility, 2) investigate the ability of inducible gain- or loss-of-function for PKCalpha to alter the progression towards heart failure in two distinct mouse models of disease, 3) examine the ability of acute pharmacologic inhibition of PKCa to potentially benefit a large animal model of heart failure. Collectively, the proposed course of investigation will span a biochemical and mechanistic evaluation of a PKCalpha function in vitro through a physiologic assessment of PKCalpha in animal models of heart failure suggesting disease ramifications in humans. Thus, this component will address the central theme of the SCCOR proposal pertaining to signaling pathways and cardiac contractile responsiveness, through investigation of single gene-function correlations.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL077101-04
Application #
7563994
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2008-01-01
Budget End
2008-12-31
Support Year
4
Fiscal Year
2008
Total Cost
$412,549
Indirect Cost
Name
University of Cincinnati
Department
Type
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Kim, Ka Eul; Tae, Hyun-Jin; Natalia, Petrashevskaya et al. (2016) Cardiac physiologic regulation of sub-type specific adrenergic receptors in transgenic mice overexpressing ?1- and ?2-adrenergic receptors. Clin Exp Emerg Med 3:175-180
Karch, Jason; Molkentin, Jeffery D (2015) Regulated necrotic cell death: the passive aggressive side of Bax and Bak. Circ Res 116:1800-9
Gupta, Manish K; Gulick, James; Liu, Ruijie et al. (2014) Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes. Circ Res 115:721-9
Sandri, Marco; Robbins, Jeffrey (2014) Proteotoxicity: an underappreciated pathology in cardiac disease. J Mol Cell Cardiol 71:3-10
Holmes, Michael V; Exeter, Holly J; Folkersen, Lasse et al. (2014) Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet 7:144-50
Correll, Robert N; Eder, Petra; Burr, Adam R et al. (2014) Overexpression of the Na+/K+ ATPase ?2 but not ?1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 114:249-256
van Berlo, Jop H; Kanisicak, Onur; Maillet, Marjorie et al. (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337-41
Gupta, Manish K; Robbins, Jeffrey (2014) Post-translational control of cardiac hemodynamics through myosin binding protein C. Pflugers Arch 466:231-6
Alves, Marco L; Dias, Fernando A L; Gaffin, Robert D et al. (2014) Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet 7:132-143
Park, Chang Sik; Chen, Shan; Lee, Hoyong et al. (2013) Targeted ablation of the histidine-rich Ca(2+)-binding protein (HRC) gene is associated with abnormal SR Ca(2+)-cycling and severe pathology under pressure-overload stress. Basic Res Cardiol 108:344

Showing the most recent 10 out of 134 publications